What does the future of nucleic acid- and nanoparticle-based therapeutics look like? As researchers work to develop new treatments for rare diseases, common cardiometabolic conditions, cancer and more, the possibilities seem endless.
From mRNA and cell therapy to CRISPR gene editing and protein replacement, the new technologies backing the latest vaccines and medicines have the potential to solve complex health problems and tackle diseases once thought untreatable.
While Cytiva works with some of the world’s most innovative and creative therapeutic developers to manufacture their groundbreaking treatments, we’re also learning how to navigate a new and diverse genomic medicine landscape. Hear from a multidisciplinary team that’s applying these lessons to stay ahead of the curve and develop scalable, GMP-ready solutions that will efficiently bring innovative therapeutics - carried by LNPs and other novel delivery technologies - to market and the clinic.
Find out how our expertise, knowledge, and experience are helping researchers and biopharma companies offer new hope for patients with rare diseases, cancer, cardiometabolic conditions, autoimmune conditions, and more.
For more stories from Cytiva, visit www.cytiva.com/behind-biopharma
For more information on our advanced therapies solutions, visit www.cytiva.com/advanced-therapies
Episode features: Scott Ripley, Lloyd Jeffs, James Taylor, Jagbir Singh, Angela Zhang.
4 июн 2024
